 ImmunoGen announced positive results from the phase 3 SORAYA trial using mirvetuximab for ovarian cancer patients, meeting both the primary and secondary endpoints. A pivotal confirmatory study using mirvetuximab, known as MIRASOL, is expected to have results out by Q3 of 2022. This confirmatory study is a crucial turning point for the company. 